Corvus Pharmaceuticals
CRVS
43 hedge funds and large institutions have $43.6M invested in Corvus Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
16% more funds holding
Funds holding: 37 → 43 (+6)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.23% less ownership
Funds ownership: 70.66% → 70.43% (-0.23%)
61% less capital invested
Capital invested by funds: $113M → $43.6M (-$69.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.15M |
| 2 |
Millennium Management
New York
|
+$942K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$202K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$184K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.52M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$816K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$508K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$431K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$124K |
CRVS Hedge Fund Activity: Q1 2020 in Review
43 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2020, worth a combined $43.6M — down 61% from $113M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CRVS positions and 5 closed out — a net gain of 7 holders — while 11 added to existing stakes and 9 trimmed.
The largest buyer was BVF Inc, adding an estimated $2.15M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $3.52M sold.
- 43 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2020, up from 37 in Q4 2019.
- Funds reported $43.6M of Corvus Pharmaceuticals stock for Q1 2020, down 61% quarter-over-quarter.
- 12 funds opened new Corvus Pharmaceuticals positions in Q1 2020 and 5 closed out, a net change of +7 holders.
- The largest Corvus Pharmaceuticals buyer in Q1 2020 was BVF Inc, an estimated $2.15M added.
- The largest Corvus Pharmaceuticals seller in Q1 2020 was T. Rowe Price Associates, an estimated $3.52M sold.
Based on aggregated 13F filings for Q1 2020.